NewsbenzingaKeros Therapeutics Q2 EPS $(1.45) Misses $(1.34) EstimateAug 3, 2026, 16:12 ET · PublishedSummaryOriginalView sourceArticle summaryPlease check the source for details.An excerpt from the original article.Related companiesKROSKROSView stockLikeCommentsRepostShareComments —CommentLoading comments…
Comments —
Loading comments…